104 related articles for article (PubMed ID: 22555108)
1. TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.
Braga Lda C; Alvares da Silva Ramos AP; Traiman P; Silva LM; Lopes da Silva-Filho A
Gynecol Oncol; 2012 Aug; 126(2):268-73. PubMed ID: 22555108
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors.
Braga Lda C; Silva LM; Piedade JB; Traiman P; da Silva Filho AL
Arch Gynecol Obstet; 2014 May; 289(5):1061-9. PubMed ID: 24190693
[TBL] [Abstract][Full Text] [Related]
3. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
[TBL] [Abstract][Full Text] [Related]
4. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
[TBL] [Abstract][Full Text] [Related]
5. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME; Ossenkoppele GJ; van Rhenen A; van Dreunen L; Jirka SM; Zevenbergen A; Schuurhuis GJ; van de Loosdrecht AA
Leuk Res; 2011 Jun; 35(6):741-9. PubMed ID: 21281967
[TBL] [Abstract][Full Text] [Related]
6. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
Arts HJ; de Jong S; Hollema H; ten Hoor K; van der Zee AG; de Vries EG
Gynecol Oncol; 2004 Mar; 92(3):794-800. PubMed ID: 14984943
[TBL] [Abstract][Full Text] [Related]
8. Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma.
Venza M; Visalli M; Catalano T; Fortunato C; Oteri R; Teti D; Venza I
Biochem Biophys Res Commun; 2013 Nov; 441(4):743-50. PubMed ID: 24211571
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Rodríguez A; Ortiz-Ferrón G; Redondo JM; López-Rivas A
J Biol Chem; 2004 Feb; 279(6):4093-101. PubMed ID: 14623878
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
12. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.
Narayan G; Xie D; Ishdorj G; Scotto L; Mansukhani M; Pothuri B; Wright JD; Kaufmann AM; Schneider A; Arias-Pulido H; Murty VV
Genes Chromosomes Cancer; 2016 Feb; 55(2):177-89. PubMed ID: 26542757
[TBL] [Abstract][Full Text] [Related]
14. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
15. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter.
Sträter J; Hinz U; Walczak H; Mechtersheimer G; Koretz K; Herfarth C; Möller P; Lehnert T
Clin Cancer Res; 2002 Dec; 8(12):3734-40. PubMed ID: 12473583
[TBL] [Abstract][Full Text] [Related]
16. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.
Sheikh MS; Huang Y; Fernandez-Salas EA; El-Deiry WS; Friess H; Amundson S; Yin J; Meltzer SJ; Holbrook NJ; Fornace AJ
Oncogene; 1999 Jul; 18(28):4153-9. PubMed ID: 10435597
[TBL] [Abstract][Full Text] [Related]
17. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
Wei SH; Chen CM; Strathdee G; Harnsomburana J; Shyu CR; Rahmatpanah F; Shi H; Ng SW; Yan PS; Nephew KP; Brown R; Huang TH
Clin Cancer Res; 2002 Jul; 8(7):2246-52. PubMed ID: 12114427
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.
Labovsky V; Martinez LM; Davies KM; de Luján Calcagno M; García-Rivello H; Wernicke A; Feldman L; Matas A; Giorello MB; Borzone FR; Choi H; Howard SC; Chasseing NA
BMC Cancer; 2017 Apr; 17(1):280. PubMed ID: 28420351
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of the TRAIL-R3 gene.
Ruiz de Almodóvar C; López-Rivas A; Redondo JM; Rodríguez A
Vitam Horm; 2004; 67():51-63. PubMed ID: 15110171
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.
Shivapurkar N; Toyooka S; Toyooka KO; Reddy J; Miyajima K; Suzuki M; Shigematsu H; Takahashi T; Parikh G; Pass HI; Chaudhary PM; Gazdar AF
Int J Cancer; 2004 May; 109(5):786-92. PubMed ID: 14999791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
